· 个股论点
涉及标的： $AXTI$NVDA$SLOIF$TSEM$TSM
改变了对Soitec ($SLOIF)的看法，建了一个约43美元的大仓位以获取CPO（共封装光学）敞口。 $NVDA下周GTC大会是推动光子学及这一架构的最大催化剂。 市值约15亿欧元，以1倍账面价值和约2倍市销率交易（估值非常低迷）。 在CPO基板方面拥有真正的垄断地位（光子学通常享有很高的溢价估值，垄断地位更是额外溢价）。 算法和分析师可能会对市场份额感到困惑，但在SOI基板上这实际上是垄断——他们授权给其他厂商如Shin Etsu是为了多样化，例如$TSM不喜欢只有一家供应商。 我不认为机构会等到明年才提前布局像Soitec这样的名字，或者$TSEM（而且大多数人甚至还没听说过$AXTI这样的名字）。 这个时机是在买入智能手机周期低迷阶段的可能底部，同时获得CPO在2027年中后期的全部上涨空间，加上下周$NVDA GTC催化剂。 我个人认为从这里还有3倍空间，所以我做多了。
Changed my mind about Soitec ( $SLOIF ) and took a sizable position ~43 for CPO exposure. $NVDA GTC next week biggest catalyst pushing photonics and this architecture. ~1.5B euros MC. Trading at 1x book value and ~2x P/S (very depressed valuations) Genuine monopoly over substrates side for CPO (typically very premium valuations for photonics + even extra premium for monopoly status) Algos and analysts might get confused over market share but it’s an actual monopoly over SOI substrates since they give licenses to other players like Shin Etsu for diversification sake eg. $TSM doesn’t like just 1. I don’t think institutions will wait until next year to frontrun these names like Soitec or $TSEM (and most probably haven’t even heard of these names like $AXTI yet) This timing would be buying the likely bottom of the depressed smartphone cycle, while getting full upside of CPO mid-late 2027 + $NVDA GTC catalyst next week. I personally think it’s a 3x from here so I went long.